AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2025
Jan 23, 2025
32407_dirs_2025-01-23_dad76ecc-28ea-4dfc-a336-3d4b9248eaee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2025-01-21
Reporting Person: Henderson Molly (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-21 | Common Stock | S | 6583 | $6.5883 | Disposed | 93546 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1911.27 | Indirect |
Footnotes
F1: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $6.5855 to $6.6519. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.